Large-scale testing (Phase 3)WithdrawnNCT01860742What this trial is testingRandomized Phase III of PRRT Versus InterferonWho this might be right forGastro-intestinal Neuroendocrine Tumors Jules Bordet Institute
Not applicableNot Yet RecruitingNCT07538791What this trial is testingItalian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)Who this might be right forPheochromocytomasParagangliomas Azienda USL Reggio Emilia - IRCCS 210
Early research (Phase 1)Looking for participantsNCT05870423What this trial is testingImproving Peptide Receptor Radionuclide Therapy With PARP InhibitorsWho this might be right forNeuroendocrine TumorsPeptide Receptor Radionuclide Therapy Erasmus Medical Center 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT02754297What this trial is testingPersonalized PRRT of Neuroendocrine TumorsWho this might be right forNeuroendocrine TumorsCarcinoid TumorCarcinoma, Neuroendocrine CHU de Quebec-Universite Laval 275
Testing effectiveness (Phase 2)Ended earlyNCT04023331What this trial is testing67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory NeuroblastomaWho this might be right forNeuroblastomaRelapsed NeuroblastomaRefractory Neuroblastoma Clarity Pharmaceuticals Ltd 21
Early research (Phase 1)UnknownNCT06081322What this trial is testingEvaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic TumorsWho this might be right forAdvanced Pancreatic Cancer and Cholangiocarcinoma Zhejiang University 29
Not applicableStudy completedNCT05427032What this trial is testingHRQoL During PRRT in Patients With NETsWho this might be right forNeuroendocrine TumorsQuality of LifePeptide Receptor Radionuclide Therapy Uppsala University 756
Testing effectiveness (Phase 2)Study completedNCT02230176What this trial is testingAntitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase IIWho this might be right forPancreatic Neuroendocrine Carcinoma Gustave Roussy, Cancer Campus, Grand Paris 84
Testing effectiveness (Phase 2)Study completedNCT04385992What this trial is testingNeoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNETWho this might be right forNeuroendocrine Tumors IRCCS San Raffaele 31
Testing effectiveness (Phase 2)Ended earlyNCT02488512What this trial is testingPeptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell LymphomasWho this might be right forDLBCLMCLRecurrent Disease Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 1
Testing effectiveness (Phase 2)Temporarily pausedNCT05198479What this trial is testingPhase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-inWho this might be right forMetastatic Nasopharyngeal Cancer National Cancer Centre, Singapore 25
Large-scale testing (Phase 3)Looking for participantsNCT06855095What this trial is testingAbsorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA TrialWho this might be right forNeuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2+1 more The Netherlands Cancer Institute 39
Testing effectiveness (Phase 2)Looking for participantsNCT04939610What this trial is testing177Lu-FAP-2286 in Advanced Solid TumorsWho this might be right forSolid Tumor Novartis Pharmaceuticals 222
Testing effectiveness (Phase 2)Looking for participantsNCT04837885What this trial is testingIntra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver MetastasesWho this might be right forNeuroendocrine TumorLiver MetastasesNeuroendocrine Gastroenteropancreatic Tumour University Hospital, Bordeaux 23
Large-scale testing (Phase 3)Looking for participantsNCT05918302What this trial is testingEfficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.Who this might be right forNeuroendocrine TumorsLung Neuroendocrine NeoplasmThymus Neoplasms Grupo Espanol de Tumores Neuroendocrinos 170
Testing effectiveness (Phase 2)WithdrawnNCT03923257What this trial is testingDosimetry Guided PRRT With 177Lu-DOTATATE in Children and AdolescentsWho this might be right forNeuroendocrine TumorsPheochromocytomaParaganglioma Sue O'Dorisio
Not applicableLooking for participantsNCT06500065What this trial is testing68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue SarcomasWho this might be right forSoft Tissue Sarcoma Ohio State University Comprehensive Cancer Center 30
Testing effectiveness (Phase 2)Ended earlyNCT02489604What this trial is testingPeptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine TumorsWho this might be right forNeuroendocrine Tumors Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 70
Not applicableLooking for participantsNCT04090034What this trial is testingPeptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine TumorsWho this might be right forNeuroendocrine TumorsGastroenteropancreatic Neuroendocrine Tumor Methodist Health System 50
Early research (Phase 1)Looking for participantsNCT05053854What this trial is testingPARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine TumoursWho this might be right forNeuroendocrine Tumors Peter MacCallum Cancer Centre, Australia 24